drugset / Trial / NCT00687245

Pharmacokinetic Study of Esomeprazole Magnesium in Patients 1 to 11 Years-Old With Endoscopically-Proven Gastroesophageal Reflux Disease (GERD)

NCT00687245

Phase 1 Completed 40 enrolled AstraZeneca
RandomizedParallel-groupOpen-label

Summary

The purpose of this study is to determine the area under the plasma concentration-time curve (AUC) of esomeprazole after single oral doses of 5 mg, 10 mg or 20 mg esomeprazole in pediatric patients 1 to 11 years-old inclusive with endoscopically-proven GERD.

Timeline

Start
2006-08
Primary completion
2008-05
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 5 mg Oral
Subject Esomeprazole Small molecule 10 mg Oral
Subject Esomeprazole Small molecule 20 mg Oral